Did Treace Medical Concepts, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TMCI ...

Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Fraud ...

财务报告与披露 - 公司发布了截至2024年12月31日的季度和年度初步未经审计财务结果[7] - 公司提交了8-K表格，包含财务结果和投资者演示文稿[11] - 公司首席财务官Mark L. Hair签署了8-K报告[15] 投资者关系与演示 - 公司计划在2025年1月14日的J.P. Morgan Healthcare Conference上进行投资者演示[9] - 投资者演示文稿已发布在公司投资者关系网站上[9] - 演示文稿将用于与分析师、投资者等的会议中[9] - 演示文稿的实时网络直播和存档记录将在公司网站投资者部分提供[9] 公司基本信息 - 公司普通股在纳斯达克全球精选市场交易，股票代码为TMCI[5] - 公司注册地为特拉华州，总部位于佛罗里达州庞特韦德拉[2] 公司治理与合规 - 公司未选择使用新兴增长公司的延长过渡期[6]

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approxi ...

Treace Medical Concepts, Inc. (TMCI) recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.This development follows Treace Medical's recent introduction of the Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, and the SpeedPlate Rapid Compression Implants, an innovative fixation platform versatile across various foot procedures.The Percuplasty Percuta ...

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am ...

Positions Treace to Significantly Increase Share of Overall Bunion Market and Expand Surgeon Customer BasePONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the limited market release and first surgical cases utilizing the Percu ...

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ platform, which is ...

PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the Adductoplasty® System for a CT-based, patient specific correction personalized to th ...